Clinical Trials Browser

Phase 1 × OTHER × Parkinson Disease × Clear all

NCT01691924 2016-03-08

Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers

Phase 1 Completed

Neoplasms, Parkinson Disease

NCT02111330 2016-03-08

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers

Phase 1 Completed

Neoplasms, Parkinson Disease